Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease. As a company, we believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives.
TypePublic
HQCarlsbad, US
Founded2008
Size (employees)91 (est)
Websiteobalon.com
Obalon Therapeutics was founded in 2008 and is headquartered in Carlsbad, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Obalon Therapeutics

Mark Brister

Mark Brister

VP of R&D
Nooshin Hussainy

Nooshin Hussainy

Financial Controller
Show more

Obalon Therapeutics Office Locations

Obalon Therapeutics has an office in Carlsbad
Carlsbad, US (HQ)
f 5421 Avenida Encinas
Show all (1)
Report incorrect company information

Obalon Therapeutics Financials and Metrics

Obalon Therapeutics Revenue

Obalon Therapeutics's revenue was reported to be $9.91 m in FY, 2017
USD

Revenue (Q2, 2018)

4.1m

Gross profit (Q2, 2018)

1.6m

Gross profit margin (Q2, 2018), %

38.7%

Net income (Q2, 2018)

(21.9m)

EBIT (Q2, 2018)

(21.7m)

Market capitalization (15-Oct-2018)

51.2m

Closing stock price (15-Oct-2018)

2.2

Cash (30-Jun-2018)

24.2m
Obalon Therapeutics's current market capitalization is $51.2 m.
Annual
USDFY, 2016FY, 2017

Revenue

9.9m

Cost of goods sold

2.8m4.8m

Gross profit

(2.8m)5.1m

Gross profit Margin, %

51%
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

773.0k1.5m2.0m1.3m4.1m

Cost of goods sold

644.0k823.0k990.0k769.0k2.5m

Gross profit

129.0k649.0k973.0k577.0k1.6m

Gross profit Margin, %

17%44%50%43%39%
Annual
USDFY, 2016FY, 2017

Cash

73.0m21.1m

Accounts Receivable

2.9m4.2m

Inventories

827.0k1.4m

Current Assets

78.1m51.8m
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

2.3m41.7m5.8m33.5m24.2m

Accounts Receivable

1.0m1.8m

Inventories

438.0k928.0k747.0k1.9m1.8m

Current Assets

18.0m69.7m63.9m39.1m31.0m
Annual
USDFY, 2016FY, 2017

Net Income

(20.5m)(34.8m)

Depreciation and Amortization

192.0k330.0k

Inventories

(464.0k)(591.0k)

Accounts Payable

46.0k624.0k
Quarterly
USDQ3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(5.3m)(7.7m)(12.1m)(21.9m)

Depreciation and Amortization

129.0k276.0k

Inventories

438.0k928.0k(449.0k)(424.0k)

Accounts Payable

1.1m823.0k1.1m275.0k
USDY, 2018

Financial Leverage

2 x
Show all financial metrics
Report incorrect company information

Obalon Therapeutics News and Updates

Global Intragastric Balloons Market 2018-2022 - Key Vendors are Allurion Technologies, Apollo Endosurgery, Helioscopie, Obalon Therapeutics, ReShape Lifesciences & Spatz FGIA

DUBLIN, Sept. 26, 2018 /PRNewswire/ -- The "Global Intragastric Balloons Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Intragastric Balloons Market to grow at a CAGR of 25.18% during the period 2018-2022. The report has been prepared based on an...

Obalon Therapeutics to Raise $10 Million in Private Placement

SAN DIEGO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN) a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has entered into a…
Report incorrect company information

Obalon Therapeutics Blogs

Obalon Therapeutics Company Life and Culture

Report incorrect company information